{"id":753250,"date":"2023-05-01T16:46:24","date_gmt":"2023-05-01T20:46:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/"},"modified":"2023-05-01T16:46:24","modified_gmt":"2023-05-01T20:46:24","slug":"revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/","title":{"rendered":"Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">REDWOOD CITY, Calif., May  01, 2023  (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2023 on Monday, May 8, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines\u2019 senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.<\/p>\n<p align=\"justify\">To listen to the live webcast, or access the archived webcast, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LeMCUwPPEV-Q4pjmh1EIkLKtISOpNQJ7Hyhihgf7AV36FW17AM8Vnv5xyNgY301uo5M8GHMeFE5H4bMxdEa1mcPjGAN6HRsFLUG9t_mPz2dhMxkoScGF0LOIhjDX70A3ZrBU3cYcwph-zCjWXTXoFOqlWQS2tkvteorYfu5j1d0=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ir.revmed.com\/events-and-presentations<\/a>. Following the live webcast, a replay will be available on the company\u2019s website for at least 14 days.<\/p>\n<p align=\"justify\">\n        <strong>About Revolution Medicines, Inc.<\/strong><br \/>\n        <br \/>Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company\u2019s R&amp;D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company\u2019s RAS(ON) Inhibitors RMC-6236 (RAS<sup>MULTI<\/sup>) and RMC-6291 (KRAS<sup>G12C<\/sup>) are currently in clinical development. Additional RAS(ON) Inhibitors in the company\u2019s pipeline include RMC-9805 (KRAS<sup>G12D<\/sup>) and RMC-0708 (KRAS<sup>Q61H<\/sup>), both of which are currently in IND-enabling development, RMC-8839 (KRAS<sup>G13C<\/sup>), and additional compounds targeting other RAS variants. RAS Companion Inhibitors currently in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1\/4EBP1).<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTA4MiM1NTY3MTYzIzIxOTQwMzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NGY1M2M5OTQtZDI1NS00YjE1LWIyYjktMTE2NGUxNGZkOTcwLTEyMDU1ODc=\/tiny\/Revolution-Medicines-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investors &amp; Media Contact:\r\nErin Graves\r\n650-779-0136\r\negraves@revmed.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2023 on Monday, May 8, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines\u2019 senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https:\/\/ir.revmed.com\/events-and-presentations. Following the live webcast, a replay will be available on the company\u2019s website for at least 14 days. About Revolution Medicines, Inc. Revolution Medicines is &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-753250","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2023 on Monday, May 8, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines\u2019 senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https:\/\/ir.revmed.com\/events-and-presentations. Following the live webcast, a replay will be available on the company\u2019s website for at least 14 days. About Revolution Medicines, Inc. Revolution Medicines is &hellip; Continue reading &quot;Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-01T20:46:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTA4MiM1NTY3MTYzIzIxOTQwMzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023\",\"datePublished\":\"2023-05-01T20:46:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\\\/\"},\"wordCount\":240,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyOTA4MiM1NTY3MTYzIzIxOTQwMzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\\\/\",\"name\":\"Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyOTA4MiM1NTY3MTYzIzIxOTQwMzQ=\",\"datePublished\":\"2023-05-01T20:46:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyOTA4MiM1NTY3MTYzIzIxOTQwMzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyOTA4MiM1NTY3MTYzIzIxOTQwMzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/","og_locale":"en_US","og_type":"article","og_title":"Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023 - Market Newsdesk","og_description":"REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2023 on Monday, May 8, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines\u2019 senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https:\/\/ir.revmed.com\/events-and-presentations. Following the live webcast, a replay will be available on the company\u2019s website for at least 14 days. About Revolution Medicines, Inc. Revolution Medicines is &hellip; Continue reading \"Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-01T20:46:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTA4MiM1NTY3MTYzIzIxOTQwMzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023","datePublished":"2023-05-01T20:46:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/"},"wordCount":240,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTA4MiM1NTY3MTYzIzIxOTQwMzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/","name":"Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTA4MiM1NTY3MTYzIzIxOTQwMzQ=","datePublished":"2023-05-01T20:46:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTA4MiM1NTY3MTYzIzIxOTQwMzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyOTA4MiM1NTY3MTYzIzIxOTQwMzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-first-quarter-2023-after-market-close-on-may-8-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/753250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=753250"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/753250\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=753250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=753250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=753250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}